****

*Presented by* 

**Weekly COVID 19 Opportunities Update**

**New Opportunities**

**August 10, 2020**

**Table of Contents**

**Health Systems Capacity Building (including public health, telemedicine and mental health)**

Department of Health and Human Services

Indian Health Service

* COVID-19 Contact Tracing Services

**Health Research Opportunities**

Department of Health and Human Services

Centers for Disease Control and Prevention – ERA

* Annual Estimates of Influenza Vaccine Effectiveness for Preventing Medically Attended Laboratory-Confirmed Influenza in the United States

National Institutes of Health

* Emergency Awards: Chemosensory Testing as a COVID-19 Screening Tool (U01 Clinical Trial Optional)
* Emergency Awards: Automatic Detection and Tracing of SARS-CoV-2 (U01 Clinical Trial Not Allowed)
* Emergency Awards: RADx-rad Wastewater Detection of SARS-COV-2 (COVID-19) (U01 - Clinical Trials Not Allowed)
* Emergency Awards RADx-RAD: Screening for COVID-19 by Electronic-Nose Technology (SCENT) (U18 Clinical Trial Not Allowed)
* Emergency Awards: Exosome-based Non-traditional Technologies Towards Multi-Parametric and Integrated Approaches for SARS-CoV-2 (U18 Clinical Trial Not Allowed)
* Emergency Awards RADx-RAD: Novel Biosensing for Screening, Diagnosis and Monitoring of COVID-19 From Skin and The Oral Cavity (R44 Clinical Trial Not Allowed)
* Emergency Awards RADx-RAD: Novel Biosensing for Screening, Diagnosis and Monitoring of COVID-19 From Skin and The Oral Cavity (Fast-Track STTR Clinical Trial Not Allowed)
* Emergency Awards: RADx-RAD Multimodal COVID-19 surveillance methods for high risk clustered populations (R01 Clinical Trial Optional)
* Emergency Awards: RADx-rad Data Coordination Center (DCC) (U24 Clinical Trial Not Allowed)
* Emergency Awards: RADx-rad Predicting Viral-Associated Inflammatory Disease Severity in Children with Laboratory Diagnostics and Artificial Intelligence (PreVAIL kIds) (R61/R33 Clinical Trial Optional)
* Urgent Phase I/II Clinical Trials to Repurpose Existing Therapeutic Agents to Treat COVID-19 Sequelae (U01 Clinical Trial Required)

**Other Relevant Opportunities**

Department of Homeland Security

FEMA

* FY20 Building Resilient Infrastructure and Communities

Department of State

Office of the Secretary

* COVID-19 Private Sector Engagement & Partnership Fund

U.S. Agency for International Development

* Board for International Food and Agricultural Development

**Health Systems Capacity Building (including public health, telemedicine and mental health)**

**Department of Health and Human Services – Indian Health Service - COVID-19 Contact Tracing Services**

**Proposal Due Date: August 21, 2020**

**Expected Number of Awards:**

**Estimated Total Program Funding:**

**Award Ceiling:**

**Award Floor:**

**Funding Opportunity Number: 75H70420R00005**

*Purpose: The Indian Health Service (IHS), an agency within the Department of Health and Human Services, is responsible for providing federal health services to American Indians and Alaska Natives (AI/AN). IHS provides a comprehensive health service delivery system for approximately 2.56 million AI/AN who belong to 573 federally recognized Tribes in 37 states.*

*In response to the COVID19 pandemic, IHS intends to assist I/T/U communities to organize, develop, and/or refine their contact tracing capabilities in accordance with Federal, State, local, Tribal and other guidance in AI/AN communities, via contract support services, and this sources sought notice is to identify potential contractor resources that are capable of providing needed services in the AI/AN communities, including in rural/remote areas. IHS is seeking sources that have current staff readily available that would meet our immediate need for contact tracing services; this is NOT for a service requirement that involves executive searches, recruiting, testing or screening potential candidates to be hired at a later date.*

*In accordance with the CDC’s Interim Guidance on Developing a COVID-19 Case Investigation & Contact Tracing Plan - Case investigation and contact tracing are fundamental activities that involve working with a patient (symptomatic and asymptomatic) who has been diagnosed with an infectious disease to identify and provide support to people (contacts) who may have been infected through exposure to the patient. This process prevents further transmission of disease by separating people who have (or may have) an infectious disease from people who do not. It is a core disease control measure that has been employed by public health agency personnel for decades. Case investigation\* and contact tracing are most effective when part of a multifaceted response to an outbreak (https://www.cdc.gov/coronavirus/2019-ncov/php/contact-tracing/contact-tracing-plan/overview.html).*

[*https://beta.sam.gov/opp/f3071bf555704e1e92420d8b52275cfd/view*](https://beta.sam.gov/opp/f3071bf555704e1e92420d8b52275cfd/view)

**Health Research Opportunities**

**Department of Health and Human Services - Centers for Disease Control and Prevention – ERA - Annual Estimates of Influenza Vaccine Effectiveness for Preventing Medically Attended Laboratory-Confirmed Influenza in the United States**

**Estimated Post Date: November 4, 2020**

**Estimated Application Due Date: January 8, 2021**

**Expected Number of Awards: 7**

**Estimated Total Program Funding: $75,500,000**

**Award Ceiling: $2,150,000**

**Award Floor: $1,440,000**

**Funding Opportunity Number: RFA-IP-21-005**

*Purpose: Influenza and other respiratory illnesses, including COVID-19, are important causes of morbidity, mortality, and healthcare burden across all age groups. For influenza vaccines, and for novel vaccines such as for COVID-19, estimates of vaccine effectiveness in preventing illness and associated complications are needed to evaluate the protection provided by nationwide vaccination programs. The goal of this notice of funding opportunity is to: a) support a network of US institutions that can obtain reliable vaccination information for a population, or cohort of individuals; b) provide accurate estimates of the effectiveness of vaccines against respiratory viruses including influenza, SARS-CoV-2 and other respiratory viruses that may emerge; and c) prevent medically attended influenza-associated illness in the population for whom influenza vaccination is recommended.*

[*https://www.grants.gov/web/grants/view-opportunity.html?oppId=328584*](https://www.grants.gov/web/grants/view-opportunity.html?oppId=328584)

**Department of Health and Human Services - National Institutes of Health - Emergency Awards: Chemosensory Testing as a COVID-19 Screening Tool (U01 Clinical Trial Optional)**

**Proposal Due Date: September 15, 2020**

**Expected Number of Awards:**

**Estimated Total Program Funding: $7,000,000**

**Award Ceiling: $500,000**

**Award Floor:**

**Funding Opportunity Number: RFA-OD-20-022**

*Purpose: NIH is issuing this RFA in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19). This emergency NOSI from the NIH provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Radical (RADx-rad) initiative. The goal of RADx-rad initiative is to encourage the development of novel, non-traditional approaches to identify the current SARS-CoV-2 virus or other markers of the COVID-19 disease that can be used in future outbreaks of COVID-19 and that could be applicable to other, as yet unknown, viruses. Specifically, the goal of this RFA is to solicit proposals to enhance the utility of chemosensory testing as a COVID-19 screening tool by using objective tests to examine the onset and prognostic value of chemosensory loss and to encourage the development and/or deployment of home-based and on-site chemosensory tests. The funding for this initiative is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020.*

[*https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-20-022.html*](https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-20-022.html)

**Department of Health and Human Services - National Institutes of Health - Emergency Awards: Automatic Detection and Tracing of SARS-CoV-2 (U01 Clinical Trial Not Allowed)**

**Letter of Intent Due Date: August 21, 2020**

**Proposal Due Date: September 15, 2020**

**Expected Number of Awards:**

**Estimated Total Program Funding: $10,000,000**

**Award Ceiling: $300,000**

**Award Floor:**

**Funding Opportunity Number: RFA-OD-20-014**

*Purpose: NIH is issuing this FOA in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19). This emergency funding opportunity announcement (FOA) from the National Institutes of Health (NIH) provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Radical (RADx-rad) initiative. The goal of this RFA is to solicit proposals for the development of novel, non-traditional approaches to identify the current SARS-CoV-2 virus or other markers of the COVID-19 disease that can be used in future outbreaks of COVID-19 and that could be applicable to other, as yet unknown, viruses. Specifically, this RFA will support the early stage development of an innovative platform that integrates aptamer biosensing with touchscreen or other digital devices to achieve real-time detection and tracing of SARS-CoV-2. The project needs to demonstrate proof-of-concept of SARS-CoV-2 detection with high sensitivity and specificity, immobilized sensor functionality, automatic signal transduction and detection by digital devices. The funding for this initiative is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020. NIH expects that all projects funded under this FOA will actively coordinate, collaborate, and share data with the RADx-rad Data Coordinating Center, as allowed, and with considerations under tribal IRB processes, as appropriate. Researchers applying to this funding opportunity are strongly encouraged to review the Data Coordinating Center (DCC) funding opportunity*

[*https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-20-014.html*](https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-20-014.html)

**Department of Health and Human Services - National Institutes of Health - Emergency Awards: RADx-rad Wastewater Detection of SARS-COV-2 (COVID-19) (U01 - Clinical Trials Not Allowed)**

**Letter of Intent Due Date: August 15, 2020**

**Proposal Due Date: September 15, 2020**

**Expected Number of Awards:**

**Estimated Total Program Funding: $19,000,000**

**Award Ceiling: $2,000,000**

**Award Floor:**

**Funding Opportunity Number: RFA-OD-20-015**

*Purpose: As one of the programs within the NIH Rapid Acceleration of Diagnostics-Radical (RADx-rad) program (https://www.nih.gov/research-training/medical-research-initiatives/radx/radx-programs#radx-rad), the RADx-rad Wastewater Detection of SARS-COV-2 (COVID-19) FOA will support wastewater-based testing (WBT) surveillance which can provide detailed mapping of the extent and spread of COVID-19. Wastewater testing has been shown to be orders of magnitude less expensive and faster than clinical screening, albeit serving as a complementary approach rather than substituting individual-level testing and screening. The purpose of this FOA is to solicit cooperative agreements both for field studies and for technology research and development projects capitalizing on partnerships with small business entities in the field of WBT, to address topics such as: investigation and demonstration of specific approaches aiming to inform and optimize sample collection; implementation and development of optimized approaches to extrapolate estimation of population-level data within the community; development of optimized intervention strategies, and incorporation of computational, statistical, and mathematical models to facilitate early detection of hotspots of virus spread. The funding for this initiative is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020.*

[*https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-20-015.html*](https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-20-015.html)

**Department of Health and Human Services - National Institutes of Health - Emergency Awards RADx-RAD: Screening for COVID-19 by Electronic-Nose Technology (SCENT) (U18 Clinical Trial Not Allowed)**

**Letter of Intent Due Date: August 18, 2020**

**Proposal Due Date: September 18, 2020**

**Expected Number of Awards: 5**

**Estimated Total Program Funding: $10,000,000**

**Award Ceiling:**

**Award Floor:**

**Funding Opportunity Number: RFA-OD-20-017**

*Purpose: The National Institutes of Health (NIH) is issuing this funding opportunity announcement (FOA) in response to the declared public health emergency issued by the Secretary, Department of Health and Human Services (DHHS), for the 2019 Novel Coronavirus (COVID-19). This emergency FOA provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Radical (RADx-rad) initiative. The goal of this initiative is to solicit applications for the development of novel, non-traditional approaches to identify the current SARS-CoV-2 virus or other biomarkers of the COVID-19 disease for use in outbreaks of COVID-19, as well as for use in future pandemics resulting from new and emerging viruses. Specifically, this FOA is seeking applications for a portable sensing device to detect volatile organic compounds (VOCs, i.e., scents or odors) emanating from skin or exhaled breath, saliva and different oral tissues from the oral cavity. These sensing devices must be able to associate VOC patterns to patients with symptomatic and asymptomatic COVID-19.*

[*https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-20-017.html*](https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-20-017.html)

**Department of Health and Human Services - National Institutes of Health - Emergency Awards: Exosome-based Non-traditional Technologies Towards Multi-Parametric and Integrated Approaches for SARS-CoV-2 (U18 Clinical Trial Not Allowed)**

**Letter of Intent Due Date: August 18, 2020**

**Proposal Due Date: September 18, 2020**

**Expected Number of Awards: 5**

**Estimated Total Program Funding: $10,000,000**

**Award Ceiling:**

**Award Floor:**

**Funding Opportunity Number: RFA-OD-20-018**

*Purpose: In response to the declared public health emergency issued by the Secretary, Department of Health and Human Services (DHHS) for the 2019 Novel Coronavirus (COVID-19), the National Institutes of Health (NIH) has launched the Rapid Acceleration of Diagnostics (RADx) project. This emergency funding opportunity announcement (FOA) from NIH provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Radical (RADx-rad) initiative for the development of novel, non-traditional approaches to identify the current SARS-CoV-2 virus or other markers of the COVID-19 disease that can be used in future outbreaks of COVID-19 and that could be applicable to other, as yet unknown, viruses. Specifically, this FOA seeks to use developed technologies for single vesicle or exosome isolation and analysis and reposition these technologies for the detection of SARS-CoV-2. The funding for this initiative is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020. NIH requires that all projects funded under this FOA will actively coordinate, collaborate, and share data with the RADx-rad Data Coordinating Center, as allowed, and with considerations under tribal IRB processes, as appropriate. Researchers applying to this funding opportunity are strongly encouraged to review the companion Data Coordinating Center (DCC) funding opportunity announcement.*

[*https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-20-018.html*](https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-20-018.html)

**Department of Health and Human Services - National Institutes of Health Emergency Awards RADx-RAD: Novel Biosensing for Screening, Diagnosis and Monitoring of COVID-19 From Skin and The Oral Cavity (R44 Clinical Trial Not Allowed)**

**Letter of Intent Due Date: August 18, 2020**

**Proposal Due Date: September 18, 2020**

**Expected Number of Awards: 5**

**Estimated Total Program Funding:**

**Award Ceiling:**

**Award Floor:**

**Funding Opportunity Number: RFA-OD-20-020**

*Purpose: The goal of this RFA is to solicit direct to Phase II SBIR proposals for development of novel, non-traditional, approaches to identify the current SARS-CoV-2 virus or other biomarkers of the COVID-19 disease for use in outbreaks of COVID-19, as well as for use in future pandemics resulting from unknown viruses. This FOA is seeking applications for innovative portable devices able to produce reliable associations between biomarkers emanating from skin and the oral cavity to patients with symptomatic and asymptomatic COVID-19. Specifically, biosensing devices are expected to target skin or the oral cavity as sampling sites. Skin biosensing must detect volatile organic compounds (VOCs, i.e. scents or odors) emanating from skin in passive and noninvasive manner for use at the point of care. In addition to VOCs, oral biosensing technologies may target a wealth of biological, chemical and physical biosignatures representative of COVID-19 that can be sampled from exhaled breath/droplets, saliva, and tissues in the oral cavity. Leveraging the accessibility of human skin and the oral cavity, this FOA seeks 1) to advance novel biosensing technologies that are innovative, safe, and effective, and 2) to implement such technologies into devices with integrated artificial intelligent (AI) systems for the detection, diagnosis, prediction, prognosis and monitoring of COVID-19 in clinical, community and everyday settings. For skin monitoring, the device can include Electronic-nose (E-nose) technology or Gas Chromatography (GC). Thus, we are calling this program, the SCENT (Screening for COVID-19 by E-Nose Technology). Biosensing devices for the oral cavity can be technologies that have been thoroughly characterized as safe and effective in preclinical studies. Non-invasive, real-time, continuous or periodic measurements of VOCs and other biomarkers in breath, and emanating from oral tissues as signatures of onset, progression, and resolution of COVID-19 are desirable.*

[*https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-20-020.html*](https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-20-020.html)

**Department of Health and Human Services - National Institutes of Health - Emergency Awards RADx-RAD: Novel Biosensing for Screening, Diagnosis and Monitoring of COVID-19 From Skin and The Oral Cavity (Fast-Track STTR Clinical Trial Not Allowed)**

**Letter of Intent Due Date: August 18, 2020**

**Proposal Due Date: September 18, 2020**

**Expected Number of Awards:**

**Estimated Total Program Funding: $3,000,000**

**Award Ceiling:**

**Award Floor:**

**Funding Opportunity Number: RFA-OD-20-021**

*Purpose: The goal of this RFA is to solicit Fast Track STTR proposals for development of novel, non-traditional, approaches to identify the current SARS-CoV-2 virus or other biomarkers of the COVID-19 disease for use in outbreaks of COVID-19, as well as for use in future pandemics resulting from unknown viruses. This FOA is seeking applications for innovative portable devices able to produce reliable associations between biomarkers emanating from skin and the oral cavity to patients with symptomatic and asymptomatic COVID-19. Specifically, biosensing devices are expected to target skin or the oral cavity as sampling sites. Skin biosensing must detect volatile organic compounds (VOCs, i.e. scents or odors) emanating from skin in passive and noninvasive manner for use at the point of care. Oral biosensing technologies may target a wealth of biological, chemical (e.g., VOCs) and physical biosignatures representative of COVID-19 that can be sampled from exhaled breath/droplets, saliva, and tissues in the oral cavity.*

[*https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-20-021.html*](https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-20-021.html)

**Department of Health and Human Services - National Institutes of Health Emergency Awards: RADx-RAD Multimodal COVID-19 surveillance methods for high risk clustered populations (R01 Clinical Trial Optional)**

**Letter of Intent Due Date: August 30, 2020**

**Proposal Due Date: September 30, 2020**

**Expected Number of Awards: 1**

**Estimated Total Program Funding: $7,000,000**

**Award Ceiling:**

**Award Floor:**

**Funding Opportunity Number: RFA-OD-20-016**

*Purpose: NIH is issuing this Funding Opportunity Announcement (FOA) in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19). This emergency FOA provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Radical (RADx-rad) initiative.*

[*https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-20-016.html*](https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-20-016.html)

**Department of Health and Human Services - National Institutes of Health - Emergency Awards: RADx-rad Data Coordination Center (DCC) (U24 Clinical Trial Not Allowed)**

**Letter of Intent Due Date: August 31, 2020**

**Proposal Due Date: September 30, 2020**

**Expected Number of Awards: 1**

**Estimated Total Program Funding: $6,200,000**

**Award Ceiling: $4,000,000**

**Award Floor:**

**Funding Opportunity Number: RFA-OD-20-019**

*Purpose: NIH is issuing this FOA in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19). This emergency FOA provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Radical (RADx-rad) initiative. Specifically, this FOA seeks to fund a single cooperative agreement for a Data Coordination Center (DCC) to serve as a communication center and data hub for RADx-rad awardees. The funding for this award is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020.*

[*https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-20-019.html*](https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-20-019.html)

**Department of Health and Human Services - National Institutes of Health - Emergency Awards: RADx-rad Predicting Viral-Associated Inflammatory Disease Severity in Children with Laboratory Diagnostics and Artificial Intelligence (PreVAIL kIds) (R61/R33 Clinical Trial Optional)**

**Letter of Intent Due Date: August 31, 2020**

**Proposal Due Date: September 30, 2020**

**Expected Number of Awards:**

**Estimated Total Program Funding: $5,000,000**

**Award Ceiling: $500,000**

**Award Floor:**

**Funding Opportunity Number: RFA-OD-20-023**

*Purpose:* *This FOA seeks to support innovative research to develop novel, new or unique and non-traditional approaches (e.g. diagnostic and prognostic biomarkers and/or biosignatures) to identify and characterize the spectrum of SARS CoV-2 associated illness, including the multisystem inflammatory syndrome in children (MIS-C) and, through a prognostic algorithm, predict the longitudinal risk of disease severity after a child is exposed to and may be infected with SARS-CoV-2 to properly tailor his or her management and optimize health outcomes.*

[*https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-20-023.html*](https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-20-023.html)

**Department of Health and Human Services - National Institutes of Health - Urgent Phase I/II Clinical Trials to Repurpose Existing Therapeutic Agents to Treat COVID-19 Sequelae (U01 Clinical Trial Required)**

**Proposal Due Date: Applications will be accepted on a rolling basis, beginning on August 6, 2020**

**Expected Number of Awards:**

**Estimated Total Program Funding:**

**Award Ceiling: $3,000,000**

**Award Floor:**

**Funding Opportunity Number: RFA-TR-20-003**

*Purpose: The purpose of this urgent funding opportunity announcement is to invite applications to repurpose existing therapeutic agents to treat Coronavirus Disease 2019 (COVID-19) sequelae and associated complications that result from Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infections. The therapeutic agent must have already completed at least a Phase I clinical trial for a different indication, and not require additional regulatory studies for the new indication prior to starting a clinical trial.*

[*https://grants.nih.gov/grants/guide/rfa-files/RFA-TR-20-003.html*](https://grants.nih.gov/grants/guide/rfa-files/RFA-TR-20-003.html)

**Other Relevant Opportunities**

**Department of Homeland Security – FEMA - FY20 Building Resilient Infrastructure and Communities**

**Proposal Due Date: January 21, 2021**

**Expected Number of Awards: 125**

**Estimated Total Program Funding: $500,000,000**

**Award Ceiling:**

**Award Floor:**

**Funding Opportunity Number: DHS-20-MT-047-00-99**

*Purpose: The Building Resilient Infrastructure and Communities (BRIC) program makes federal funds available to states, U.S territories, Indian tribal governments, and local communities for pre-disaster mitigation activities. The guiding principles of the program are to: (1) support state and local governments, tribes, and territories through capability- and capacity-building to enable them to identify mitigation actions and implement projects that reduce risks posed by natural hazards; (2) encourage and enable innovation while allowing flexibility, consistency, and effectiveness; (3) promote partnerships and enable high-impact investments to reduce risk from natural hazards with a focus on critical services and facilities, public infrastructure, public safety, public health, and communities; (4) provide a significant opportunity to reduce future losses and minimize impacts on the Disaster Relief Fund (DRF); and (5) support the adoption and enforcement of building codes, standards, and policies that will protect the health, safety, and general welfare of the public, take into account future conditions , and have long-lasting impacts on community risk-reduction, including for critical services and facilities and for future disaster costs.*

*In FY20 BRIC, FEMA will provide State/Territory allocations of $600,000 to states and territories and a Tribal Set-Aside of $20,000,000 for Indian tribal governments (federally-recognized) for mitigation projects and capability- and capacity-buildling (C&CB) activities. Any funds which are not awarded from the State/Territory Allocation or Tribal Set-Aside will be re-allocated to the national competition for mitigation projects.*

[*https://www.grants.gov/web/grants/view-opportunity.html?oppId=328472*](https://www.grants.gov/web/grants/view-opportunity.html?oppId=328472)

**Department of State - Office of the Secretary - COVID-19 Private Sector Engagement & Partnership Fund**

**Proposal Due Date: May 28, 2021**

**Expected Number of Awards:**

**Estimated Total Program Funding: $10,000,000**

**Award Ceiling: $50,000**

**Award Floor:**

**Funding Opportunity Number: SFOP0007088**

*Purpose: The U.S. Department of State, Office of Global Partnerships (E/GP) is pleased to announce the COVID-19 Private Sector Engagement & Partnership Fund (Fund) Annual Program Statement (APS) that will be used make assistance awards.. This APS is being done in partnership the U.S. Agency for International Development and concept papers may be transferred to the Agency based upon a determination of suitability for award and administration. USAID’s policies and procedures will apply to concept papers that are transferred to the Agency. This APS utilizes a two-step process. Applicants must first submit a concise (5-page) concept paper designed to clearly communicate their program idea and objectives. This is not a full proposal. The purpose of the concept paper is to allow applicants to submit program ideas for evaluation prior to requiring the development of a full proposal application. After merit review of eligible concept papers, selected applicants will be invited to expand on their program idea(s) by submitting a full proposal application. Full proposals will go through a second merit review before a final funding decision is made. E/GP has outlined the process through which potential applicants may apply in Appendix 1 to this APS.*

[*https://www.grants.gov/web/grants/view-opportunity.html?oppId=328509*](https://www.grants.gov/web/grants/view-opportunity.html?oppId=328509)

**U.S. Agency for International Development - Board for International Food and Agricultural Development**

**Meeting Date: September 14, 2020**

*Purpose: Pursuant to the Federal Advisory Committee Act, notice is hereby given of a public meeting of the Board for International Food and Agricultural Development (BIFAD), COVID-19 and Nutrition: Impacts, Field Innovations, and the Way Forward. The meeting will be held on September 14, 2020 from 10:00 a.m. to 12:30 p.m. EDT at http://www.aplu.org/​projects-and-initiatives/​international-programs/​bifad/​bifad-meetings.html. A public comment period is scheduled from 11:50 a.m. to 12:15 p.m. EDT.*

*The meeting provides dedicated time to discuss how the global community can work together to protect and advance nutrition outcomes across sectors during COVID-19 response and recovery. In real time, researchers and implementers are gathering evidence to better understand the impacts of the pandemic and learning how to respond.*

*The meeting will be organized to achieve three objectives:*

*1. To provide an update on what emerging research and data can tell us about the current and expected impacts of COVID-19 containment and control measures on nutrition, and how we should use this emerging evidence to guide our response.*

*2. To learn from our implementing partners and USAID Missions across sectors that have pivoted their implementation to respond to COVID-19 and protect nutrition outcomes. To understand the realities on the ground, and to include the innovations and expertise of those on the frontlines in the discourse.*

*3. To discuss and prioritize actions for the near, medium, and long term to safeguard and accelerate nutrition progress*

[*https://www.federalregister.gov/documents/2020/08/10/2020-17387/board-for-international-food-and-agricultural-development*](https://www.federalregister.gov/documents/2020/08/10/2020-17387/board-for-international-food-and-agricultural-development)